The Regimen of Computed Tomography Screening for Lung Cancer

Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program

Claudia I. Henschke, PhD, MD, * † Rowena Yip, MPH, * Dorith Shaham, MD, † Javier J. Zulueta, MD, § Samuel M. Aguayo, MD, † Anthony P. Reeves, PhD, || Artit Jirapratanakul, PhD, * Ricardo Avila, MS, § Drew Moghannak, MD, MPH, #
David F. Yankelevitz, MD, and * for the I-ELCAP Investigators

Abstract: We learned many unanticipated and valuable lessons since we started planning our study of low-dose computed tomography (CT) screening for lung cancer in 1991. The publication of the baseline results of the Early Lung Cancer Action Project (ELCAP) in Lancet 1999 showed that CT screening could identify a high

From the *Department of Radiology, Icahn School of Medicine at Mount Sinai, New York; †Department of Electrical and Computer Engineering, Cornell University, Ithaca; §Accumetra LLC, Clifton Park, NY; ‡Department of Medical Imaging, Hadassah Medical Center, Jerusalem, Israel; §Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain; Phoenix Veterans Affairs Health Care System, Phoenix, AZ; and #Department of Radiation Oncology, Atlanta VA Medical Center, Decatur, GA.

I-ELCAP Investigators: Mount Sinai School of Medicine, New York, NY: Claudia I. Henschke, Principal Investigator, David F. Yankelevitz, Rowena Yip, Artit Jirapratanakul, Raja Flores, Andrea Wolf, Weill Cornell Medical College, New York; Dorothy I. McCauley, Mildred Chen, Daniel M. Libby, James P. Smith, Mark Pamanterre: Cornell University, Ithaca, NY: A. P. Reeves, CBNS, CBNS, University of New York at Queens College, Queens, NY: Steven Markowitz, Albert Miller, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain: Jose Cervera Deval; University of Toronto, Princess Margaret Hospital, Toronto, ON, Canada: Heidi Roberts, Demetris Patisos; Azumi General Hospital, Nagano, Japan: Shusuke Sone, Takauki Hanaoka; Clinica Universitaria de Navarra, Pamplona, Spain: Javier Zulueta, Juan P. de Torres, Maria D. Lozano; Swedish Medical Center, Seattle, WA: Ralph Aye, Kristin Manning; Christiana Care, Helen F. Graham Cancer Center, Newark, DE: Thom Bauer; National Cancer Institute Regina Elena, Rome, Italy: Stefano Canitano, Salvatore Guanta; St.Agnes Cancer Center, Baltimore, MD: Enser Cole; LungenZentrum Hirslanden, Zurich, Switzerland: Karl Klinger; Columbia University Medical Center, New York, NY: John H.M. Austin, Gregory D. N. Pearson; Hadassah Medical Organization, Jerusalem, Israel: Dorith Shaham; Holy Cross Hospital Cancer Institute, Silver Spring, MD: Cheryl Aylesworth; Nebraska Methodist Hospital, Omaha, NE: Patrick Meyers; South Nassau Communities Hospital, Long Island, NY: Shahroury Andaz; Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA: Davood Vafai; New York University Medical Center, New York, NY: David Naidich, Georgeann McGuinness; Dorothy E. Schneider Cancer Center, Mills-Peninsula Health Services, San Mateo, CA: Barry Sheppard; State University of New York at Stony Brook, Stony Brook, NY: Matthew Rikfik; ProHealth Care Regional Cancer Center, Waukesha & Oconomowoc Memorial Hospitals, Oconomowoc, WI: M. Kristin Thoren, Richard Hansen; Mainmonides Medical Center, Brooklyn, NY: Samuel Kopek; Wellstar Health System, Marietta, GA: William Mayfield; St. Joseph Health Center, St. Charles, MO: Dan Ludick; Roswell Park Cancer Institute, Buffalo, NY: Donald Klippenstein, Alan Litwin, Peter A. Loud; Upstate Medical Center, Syracuse, NY: Leslie J. Kohnman, Ernest M. Scalzetti; Jackson Memorial University, Miami, FL; Richard Thurter, Nester Villanizar; State University of New York, North Shore-Long Island Jewish Health System, New Hyde Park, NY: Afia Khan, Rakesh Shah; The 5th Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China: Xueguo Liu; Mercy Medical Center, Rockville Center, NY: Gary Herzog; Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan: Diana Yeh; National Cancer Institute of China, Beijing, China: Ning Wu; Staten Island University Hospital, Staten Island, NY: Joseph Lowry, Mary Salvatore; Central Main Medical Center, Carmine Frumiento; Mount Sinai School of Medicine, New York, NY, New York, NY: David M. Mendelson; Georgia Institute for Lung Cancer Research, Atlanta, GA: Michael V. Smith; The Valley Hospital Cancer Center, Paramus NJ: Robert Korst; Health Group Physmed/McGill University, Montreal, CA: Jana Taylor; Memorial Sloan-Kettering Cancer Center, New York; Michelle S. Grannis, Arnold Rotter; Evanston Northwestern Healthcare Medical Group, Evanston, IL: Daniel Ray; Greenovis Health, Greenville, CT: David Mullen; Our Lady of Mercy Medical Center, Bronx, NY: Peter H. Wiernik; Baylor University Medical Center, Dallas, TX: Edson H. Cheung; Sequoia Hospital, Redwood City, CA: Melissa Lim; Glens Falls Hospital, Glens Falls, NY: Louis DeCunzo; Atlantic Medical Imaging, Atlantic City, NJ: Robert Glassberg; Karmanos Cancer Institute, Detroit, MI: Harvey Pass, Carmen Endress; Rush University, Chicago, IL: Mark Yoder, Palmi Shah; Building Trades, Oak Ridge, TN: Laura Welch; Sharp Memorial Hospital, San Diego, CA: Michael Kalafer; Newark Beth Israel Medical Center, Newark, NJ: Jeremy Green; Guthrie Cancer Center, Sayre, PA: James Walsh, David Bertsch; Comprehensive Cancer Centers of the Desert, Palm Springs, CA: Eliner Camacho; Dickstein Cancer Treatment Center, White Plains Hospital, White Plains, NY: Cynthia Chin; Presbyterian Healthcare, Charlotte, NC: James O'Brien; University of Toledo, Toledo, OH: James C. Willey.

Dr D.F.Y. is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF), are nonexclusively licensed to General Electric. As an inventor of these patents, Dr D.F.Y. is entitled to a share of any compensation that CRF may receive from its commercialization of these patents. He is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision making. Dr D.F.Y. also serves on the advisory board of GRAIL. Dr C.I.H. is the President and serves on the board of the Early Diagnosis and Treatment Research Foundation. He receives no compensation from the Foundation. The Foundation is established to provide grants for projects, conferences, and public databases for research on early diagnosis and treatment of diseases. Dr C.I.H. is also a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest, which are owned by Cornell Research Foundation (CRF). Since 2009, Dr C.I.H. does not accept any financial benefit from these patents including royalties and any other proceeds related to the patents or patent applications owned by CRF. The remaining authors declare no conflicts of interest.

Correspondence to: Claudia I. Henschke, PhD, MD, Department of Radiology, P.O. Box 1234, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Place New York, NY 10029 (e-mail: claudia.henschke@mountsinai.org).

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: 10.1097/RTI.0000000000000538

www.thoracicimaging.com / Thorac Imaging • Volume 36, Number 1, January 2021

6
proportion of early, curable lung cancers. This stimulated large national screening studies to be quickly started. The ELCAP design, which provided evidence about screening in the context of a clinical program, was able to rapidly expand to a 12-institution study in New York State (NY-ELCAP) and to many international institutions (International-ELCAP), ultimately working with 82 institutions, all using the common I-ELCAP protocol. This expansion was possible because the investigators had developed the ELCAP Management System for screening, capturing data and CT images, and providing for quality assurance. This advanced registry and its rapid accumulation of data and images allowed continual assessment and updating of the regimen of screening as advances in knowledge and new technology emerged. For example, in the initial ELCAP study, introduction of helical CT scanners had allowed imaging of the entire lungs in a single breath, but the images were obtained in 10 mm increments resulting in about 30 images per person. Today, images are obtained in submillimeter slice thickness, resulting in around 700 images per person, which are viewed on high-resolution monitors. The regimen provides the imaging acquisition parameters, imaging interpretation, definition of positive result, and the recommendations for further workup, which now include identification of emphysema and coronary artery calcifications. Continual updating is critical to maximize the benefit of screening and to minimize potential harms. Insights were gained about the natural history of lung cancers, identification and management of nodule subtypes, increased understanding of nodule imaging and pathologic features, and measurement variability inherent in CT scanners. The registry also provides the foundation for assessment of new statistical techniques, including artificial intelligence, and integration of effective genomic and blood-based biomarkers, as they are developed.

**Key Words:** pulmonary nodules, screening, growth, nodule management, nodule measurement accuracy, subsolid nodules 

*(J Thorac Imaging 2021;36:6–23)*

**THE BEGINNING**

The Early Lung Cancer Action Project (ELCAP) of low-dose computed tomography (LDCT) screening lung cancer was stimulated by several research retreats in 1991 and 1992.1,2 The ELCAP study used an innovative design for the first comparison of LDCT with chest radiographic (CXR) screening to assess the stage distribution resulting from each imaging test within 2 years, separately for baseline and annual repeat rounds and the resulting lung cancer cure rates after treatment and long-term follow-up (Fig. 1). The study design also allows for random assignment of patients diagnosed with lung cancer to alternative treatments.3–10

The baseline round showed that 85.1% of the LDCT-detected lung cancer patients had clinical stage I disease, and CXR missed 82% of them.11 These results gave renewed hope to people at risk of lung cancer throughout the world.11

The annual repeat screenings were completed, submitted for publication in 1999, and published in 2001.11,10 Annual rounds are important, as they are repeated year after year, while the baseline round is performed only once. Annual rounds are pooled, as each round is a repeat occurrence of prior annual rounds, and thus are critical for evaluation of long-term screening performance. Compared with the baseline round of ELCAP, annual screening identified far fewer new noncalcified nodules (NCNs) (2.5% vs. 23%, P < 0.0001) and a lower percentage of screen-diagnosed lung cancers (0.59% vs. 2.7%, P < 0.0001); the median tumor size was smaller (8 vs. 10 mm, P = 0.45), and the percentage of screen-diagnosed Stage I disease was slightly lower (85.7% vs. 85.1%, P = 1.00). When interim, symptom-prompted diagnosed cases between rounds of screening were included, the percentage of Stage I diagnoses under screening, was lower (77.8% vs. 85.1%, P = 0.63). This was anticipated, as more aggressive cancers are identified in repeated rounds of screening than in the baseline round due to a phenomenon called “length bias.” Length bias affects all screening programs for cancer and chronic diseases.1,12–14 A later publication provided the extent of length bias.15

The success of ELCAP was due to its design, which provided screening to a cohort of people at risk for lung cancer in a clinical program, to the ELCAP Management System16 for management and quality assurance, and to the advanced registry, which stored both radiologic images and data. Since 2000, the ELCAP paradigm allowed for continued expansion of LDCT screening to New York State (NY)-ELCAP,17 and to over 80 institutions in 10 countries (International [I]-ELCAP),18 all using a common protocol.19 The common protocol and management system allowed for the emerging data to be pooled and analyzed in an efficient manner, as widespread interest in screening soon became apparent.20–23

By 2006, the expanded I-ELCAP collaboration provided sufficient data for annual follow-up of annual LDCT screening to estimate the cure rate without lead-time bias.1,2,12–14 On the basis of 10-year Kaplan-Meier survival analysis, the estimated cure rate was 80% (95% confidence interval [CI]: 74%–85%) for all lung cancers diagnosed under screening (ie, both screening-diagnosed and interim-diagnosed), and, for those in clinical Stage I and whose cancer was resected within 2 months of diagnosis, the rate was 92% (95% CI: 88%–95%).18

These rates have been updated at each of the 41 International Conference on Screening for Lung Cancer meetings, held every 6 months since 1999, and they have remained at the same level.24 The cure rate of 80% had already been suggested by Drs Flehinger and Kimmel,25–26 as the ELCAP Investigators had asked them to estimate the potential cure rate of computed tomography (CT) screening using their mathematical model. The same rate has also been estimated on the basis of the stage distribution achieved in ELCAP.8

The low-cost, efficient, prospective ELCAP cohort design provided pertinent information after 2 rounds of screening on the tumor size at detection, the stage shift,1,10 and, after appropriate follow-up, the cure rates.18 The ELCAP results were discussed in detail at the National Cancer Institute Board of Scientific Advisors meetings in 1999,27 and some experts thought that the 1999 ELCAP report provided sufficient evidence to start LDCT screening, while others thought that randomized trials were needed, and different possible future studies were discussed. Thus, stimulated by the ELCAP results, planning for several large national screening randomized controlled trials was quickly started, and, in November 2001, the Board approved the Request for Proposal, which led to the National Lung Screening Trial (NLST). The NLST provided 3

---

**FIGURE 1.** The ELCAP design allows for direct comparison of different screening tests (eg, imaging tests or biomarkers) by providing the baseline round followed by as many repeat rounds of screening as needed to assess the particular comparison.

---

This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.
rounds of screening and reported its results 9 years later in 2011. The NELSON Trial started in 2004, provided 4 rounds of screening, and it reported its preliminary results 14 years later in 2018, and its final results in 2020. In Italy, the MILD Trial started in 2005, and it reported its interim results in 2012, and its final results in 2019, 14 years later. These randomized trials confirmed the benefit originally reported by ELCAP.

Comparisons of the ELCAP study design and randomized trials and their respective outcome measures are given in several publications. These combined results have led to the increasing worldwide acceptance, as was fully evident at the 20th World Conference on Lung Cancer (WCLC) in Barcelona in September 2019.

Concerns, other than those about the screening regimen, were addressed by the I-ELCAP investigators. As to who would benefit from LDCT screening, they provided the methodology to calculate the individualized benefit for an individual enrolling in an LDCT screening program, given the person’s particular age, smoking history, and competing causes of death. The 2007 article showed how the same approach is used to calculate the survival gain of each subsequent annual round of screening. To address the concern that screening would provide a smoker the license to continue or to resume smoking, the ELCAP Investigators showed that smoking cessation increased when integrated in a program of LDCT screening and that it did not lead to resumption of smoking among former smokers. The investigators also developed recommendations for the many additional findings that could be identified on the LDCT of the chest and showed how these provided an added benefit of screening. These recommendations were added to the I-ELCAP protocol. In particular, they recognized that screening allowed for early detection of cardiovascular and chronic obstructive pulmonary disease. The 2 leading causes of death in the United States. To address the concerns about the costs of screening and follow-up, cost-effectiveness of screening was also addressed.

Unfortunately, these cost-effectiveness analyses do not incorporate the benefit of identifying early and unsuspected cardiovascular and pulmonary disease, which can be diagnosed on the same LDCT.

The I-ELCAP database includes over 82,000 participants with long-term follow-up at 82 institutions in 10 countries in the world. To address the concerns about the identification of many NCNs and unnecessary workup, stimulated in part by the advances in CT scanners and large computer monitors that allowed for identification of many tiny NCNs, the I-ELCAP investigators provided a detailed analysis of screening results using the accumulating screening results obtained with the latest scanners. Initially, they demonstrated that these advances in scanner technology were useful in decreasing the frequency of symptom-prompted, interim diagnoses between rounds of screening.

This review focuses on the lessons learned about the regimen of screening and how important it is to continually update regimen in light of continually advancing technology and knowledge to remain state-of-the-art. We address the need for assessment of the LDCT measurement accuracy, as this increases the accuracy of the recommendations and thus the benefit and efficiency of the regimen. We also show how we used the I-ELCAP data and image repository to address the concerns of overdiagnosis and overtreatment. To maximize the benefit of screening, updates in early lung cancer staging and treatment are critical, particularly in the context of the earlier diagnoses provided by effective screening. This was addressed by setting up a treatment cohort of Stage I lung cancer patients to compare treatment alternatives in the context of clinical care, this had been recommended by the Institute of Medicine. The concerns raised and the lessons learned in addressing the concerns in order to maximize the benefit of screening and minimize its potential harms are provided in the following sections.

DEVELOPMENT OF THRESHOLD VALUES FOR WORKUP OF NCN

As early as 1992, new helical CT scanners enabled acquisition of multiple LDCT images with slice thickness of 10 mm, allowing the entire chest to be scanned in a single breath-hold. Previously, CT images had been acquired one slice at a time using the “stop and shoot” approach, so that several breath-holds were required to cover the lungs. Because of the different inspiratory effort for each breath-hold, entire sections of the lungs could be missed. The new CT technology also provided adequate images at low-radiation exposures. The 30 LDCT images of each of the initial 1,000 ELCAP participants, however, were still displayed on a single radiographic film. The focus, based on previous CXR experience, was to identify a “solitary” NCN.

Once LDCT screening started, the ELCAP investigators learned that they frequently detected multiple small NCNs in a single screening participant, but only a few of them turned out to be lung cancers. Thus, multiple NCNs were documented, instead of a single one, and the protocol focused on the largest NCN. Upon retrospective reflection in writing this article, the high proportion of Stage I lung cancers, both on the baseline and annual repeat rounds, is surprising, given the small CT images that were displayed on a single radiographic film.

Subsequent advances in CT scanners provided submillimeter images, and the single CT images could be viewed on high-resolution computer monitors. This led to a marked increase in nodules being detected, but a decrease in symptom-prompted lung cancer diagnoses between screenings. This is surprising, given the small CT images that were displayed on a single radiographic film.

Thus, the ELCAP Investigators used the ELCAP database of the original 1000 participants to update the threshold values for the regimen of screening. Starting in 2000, the updated I-ELCAP protocol recommended a threshold of 5.0 mm for the workup of NCNs identified at baseline and 3.0 mm for new or growing NCNs on annual repeat screenings. This protocol was used for NY-ELCAP and I-ELCAP studies. The ELCAP Investigators also provided the requested empiric evidence for the Fleischner Society guidelines.

By 2012, with continued CT scanner advances that provided CT images with thinner slice thickness, the threshold values for the I-ELCAP protocol were again reviewed. This time, both the I-ELCAP and NLST databases were used to examine how to reduce unnecessary workup while still diagnosing lung cancers early. A threshold of 6.0 mm for the workup of baseline NCNs was chosen by the I-ELCAP Investigators. 6 mm by the American College of Radiology (ACR) and also by the National Comprehensive Cancer Network (NCCN) Investigators. The threshold for workup on new or growing NCNs on annual repeat screening in I-ELCAP remained the same, at 3.0 mm for the I-ELCAP Investigators and 4 mm for the ACR and NCCN Investigators. The implications of rounding by using a threshold of 6 mm instead of 6.0 mm were subsequently examined and the use of 6 mm led to an increase of 28.9% in the frequency of positive findings. Subsequently in 2019, the ACR changed its threshold from 6 to 6.0 mm.

This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.
REFINEMENTS OF THRESHOLD VALUES AND WORKUP RECOMMENDATIONS BY NODULE CONSISTENCY

Radiologists in Japan had been performing radiographic screening for pulmonary tuberculosis since 1935. In the 1950s, when effective tuberculosis drugs emerged, radiographic screening for tuberculosis in Japan was changed to screening for lung cancer. When lung cancer became the leading cause of cancer death in Japan in 1993, the Anti-Lung Cancer Association, a for-profit organization, added CT to the already existing program of chest radiography and sputum cytology screening provided to its due-paying members. In 1996, the Anti-Lung Cancer Association reported that 1369 members had undergone chest radiography, CT, and sputum cytology between September 1993 and April 1995, with a resulting diagnosis of lung cancer in 15, all of them by CT alone.

Japanese investigators published on a newly recognized subtype of nodules on CT, called “ground-glass” opacities, starting in 1995. I-ELCAP Investigators also identified “ground-glass” opacities on LDCT screening when they started in 1992. After much reflection, including discussion with Japanese investigators, the I-ELCAP Investigators thought it was important to differentiate these nodule subtypes from other ground-glass opacities that were due to pulmonary edema, diffuse infections, end-stage adult respiratory distress, and other entities and developed a new terminology for these NCNs based on their consistency—solid, part-solid, and nonsolid NCNs. After discussion with Dr Sone an I-ELCAP Investigator who headed the Nagano screening program, the I-ELCAP protocol set the threshold for workup of nonsolid NCNs at 8.0 mm, as this size implied that the NCN was no longer contained within a single pulmonary acinus.

To better understand these different subtypes of NCNs and lung cancers manifesting in these NCNs, starting in 2000, the I-ELCAP Investigators studied them, and developed a pathology protocol and held multiple expert pathology panel reviews, funded in part by the American Cancer Society. This led to multiple publications of the I-ELCAP Investigators with the expert lung pathologists, Drs William Travis, Darryl Carter, Masayuki Noguchi, Elisabeth Brambilla, and Adi Gazdar. Figure 2 provides the Kaplan-Meier survival rates for adenocarcinomas by the percentage of the lepidic (previously called bronchoalveolar carcinoma or BAC) component for patients with nonsolid NCNs or part-solid NCNs on CT images. As previously shown by Noguchi et al, survival of patients was 100% for patients who had 90% to 100% lepidic (BAC) component. Lepidic growth on pathology manifested radiologically as an area of "ground-glass" or nonsolid NCNs on CT. The radiologic-pathologic panel reviews ultimately led to the new pathologic classification of adenocarcinoma and revised World Health Organization classifications. The pathology guidelines also recommended that CT images be reviewed when making pathologic diagnoses of these subsolid (ie, nonsolid and part-solid) NCNs.

By 2013, the I-ELCAP Investigators thought that further updating of the regimen was needed for the workup of these NCN subtypes. For this purpose, they reviewed the I-ELCAP and NLST databases, and the world’s English publications. These detailed reviews found that nonsolid of any size and part-solid cancers with solid component <10 mm had lung cancer survival rates of essentially 100% and could be safely followed-up with annual CT until the solid component either develops within a nonsolid NCN or the solid component of the part-solid grows. These findings resulted in updated recommendations for work-up of nonsolid, part-solid, and solid NCNs given in the latest I-ELCAP protocol.

Our systematic review found that there is a lack of consensus as to the definition of part-solid NCNs. I-ELCAP investigators decided that a standardized size definition of the upper limit of solid component of a part-solid nodule was...
needed to avoid misclassification of solid NCNs as part-solid NCNs. In the NLST image database,98,99 solid lung cancers and benign nonmalignant lesions had or developed a surrounding ground-glass or nonsolid halo, but these were still solid NCNs. Similarly, solid NCNs with central cavitation were misclassified as part-solid NCNs. As a result, the I-ELCAP protocol set a size limit of 80% for the solid component of part-solid NCNs.45 The I-ELCAP investigators also found that cell types and survival rates were different for lung cancer patients who had part-solid cancers with 1% to 79% solid component and those with ≥80% solid component. After a detailed review of CT and pathology images, both pathologists and the I-ELCAP investigators recognized that the threshold values should be based on the solid component of sub-solid NCNs rather than the entire size of the NCN.

The updated I-ELCAP protocol was the first to recommend “watchful waiting” for all nonsolid NCNs by 12-month follow-up, as these had no solid component other than blood vessels within the NCN. Follow-up of part-solid and solid NCNs was based on the size of the solid component.45 This recommendation was supported by both the pathology results91 and the evidence of the long lead-time of cancers by cell-type and survival rates. The consequence of length-bias is that an optimal regimen of screening should use different threshold values and percentage of the lepidic component within the cancer on pathology. The length-bias, as a result of the threshold values, allows for misclassification, which makes I-ELCAP the most consistent protocol, providing the most information on the screening biases.

**OVERDIAGNOSIS BIAS**

Concern about overdiagnosis bias was raised for lung cancers, particularly for those diagnosed in nonsolid NCNs that had 100% survival, when resected, as reported by Noguchi and his colleagues in 1995.78 These cancers in nonsolid NCNs are diagnosed in 15% of the all the cancers.
diagnosed as a result of baseline screening and in 10% of all cancers diagnosed as a result of annual rounds (Fig. 3).

The National Cancer Institute addressed the issue of overdiagnosis and suggested that the word “cancer” be restricted to “lesions that had a reasonable likelihood of lethal progression if left untreated.”104 The panel suggested “indolent lesions of epithelial origin (IDLE)” for such lesions. Separately, the NLST investigators estimated that 18.5% of all lung cancers detected by LDCT screening in the NLST to be overdiagnosed (95% CI: 5.4%–30.6%).105 After longer follow-up, however, the NLST reported that the frequency of cancers detected in the control group reached (95% CI: 5.4%–30.6%).103 After longer follow-up, however, the NLST reported that the frequency of cancers detected in the control group reached those in the screened group.106 The NELSON investigators estimated that overdiagnosis was <8.9%.107 Recognition that adenocarcinoma-in-situ and minimally invasive adenocarcinoma are very slow-growing cancers emerged from careful investigations of radiologic-pathologic correlations of lung cancers in the context of clinical care.78–90

The I-ELCAP Investigators also studied overdiagnosis.107–117 They suggested that the concept of overdiagnosis is a malformed concept, as it is not based on clinically based manifestations of the cancer, but rather death from the cancer, as its definition uses the cause of death.117 In other words, this definition implies that a cancer is genuine only if it causes death, otherwise the cancer is an overdiagnosed one.

We suggest an alternative definition that is based on the aggressiveness of the cancer. A slow-growing cancer is overdiagnosed when it is considered to be an aggressive cancer, and an aggressive cancer is underdiagnosed when it is considered to be a slow-growing cancer. Only 10% of lung cancers diagnosed on annual repeat screenings occurred in nonsolid NCNs (Fig. 3B). In the I-ELCAP experience, these nonsolid NCNs have been followed-up for up to 28 years, and, among them, some develop solid components that grow and ultimately require treatment. We are currently studying growth rates of lung cancers to further address this issue.118

The main problem of overdiagnosis, however, is not early diagnosis but overtreatment of these indolent, slow-growing cancers, particularly when found early by screening. The goal is to avoid overtreatment. For this reason, the I-ELCAP protocol started to recommend “watchful waiting” by annual screening of nonsolid NCNs until a solid component emerges.45,82 For part-solid nodules with solid components, follow-up diagnostics are recommended according to the size of the solid component.45,96–103 If follow-up CT showed growth of the solid component of the NCN at a malignant rate, biopsy was recommended. Current surgical recommendations for nonsolid NCNs also consider watchful waiting as an alternative approach, which is also recommended by the LungRADs72,76 and National Comprehensive Center Network guidelines.74

**PROBABILITY OF LUNG CANCER IN NCN IDENTIFIED IN BASELINE AND ANNUAL REPEAT ROUNDS**

Figure 4 provides the probability of diagnosing lung cancer by the average diameter and consistency of the largest NCN in the I-ELCAP database of 76,411 participants, separately (a) baseline cancers and (b) annual repeat cancers.45 Comparison of Figures 4A and B clearly shows the differences between the baseline and all subsequent rounds. For example, for solid NCNs <6.0 mm, the probability of malignancy is >6 times higher on annual repeat rounds than on the baseline round (2.0% vs. 0.3%), while the probability of malignancy for the larger size solid nodules on annual repeat screening is about half that on baseline.

**LESSONS LEARNED ABOUT NCN GROWTH ASSESSMENT BEFORE INVASIVE WORKUP**

In the 1990s, when an NCN ≥10 mm was identified on the CT screening, the standard of care called for an immediate biopsy,8,61–66 based on CXR images. PET scans had not yet been widely introduced at that time. The first 1000 ELCAP participants whose largest NCNs were <10 mm were re-imaged 3 months later using single-slice, axial mode targeted CT acquisition rather than helical mode acquisition, as this provided higher resolution images, which allowed for more accurate assessment of growth,8,10 but if the NCN was 10 mm or larger, biopsy was recommended.

D.F.Y., an ELCAP investigator, thought that volumetric measurement was a better tumor size assessment tool than the conventional 1-dimensional or 2-dimensional measurements and studied this in the early 1990s.119–133 In 1996, Dr Anthony Reeves, an electrical and computer engineer at Cornell University in Ithaca, and his doctoral students joined the

---

**FIGURE 4.** Provides the probability of diagnosing lung cancer by the largest NCN average diameter (mm) and consistency in the I-ELCAP database, separately on the (A) baseline round and (B) annual repeat rounds.45

---

*This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.*
ELCAP research efforts and introduced 3-dimensional volumetric growth assessment. Volume-doubling time (VDT) was found to be a useful measure of growth for distinguishing between malignant and nonmalignant NCNs and also to distinguish minimally aggressive from aggressive adenocarcinomas, which had already been recognized earlier using CXR images. The ELCAP Investigators presented these volumetric analyses at many conferences, as well as at their International Conferences, and its usefulness was quickly recognized by others and integrated into emerging regimes of screening. Future investigators of the NELSON Trial, for example, attended multiple I-ELCAP and other conferences at which the ELCAP Investigators presented their volumetric results, and they incorporated volumetric analysis in the regimen of their randomized trial. The ELCAP investigators continued to work with the NELSON Investigators and assisted them in developing a management system, as they were doing with many other investigators throughout the world.

As LDCT screening expanded in I-ELCAP, the investigators found that only 18% of the baseline solid NCNs between 10 and 15 mm were malignant NCNs (eg, mostly hamartomas, granulomas, fibrosis), as shown in Figure 4A, and that, often, the nonmalignant solid NCNs had spiculated and other irregular features, typically associated with malignant NCNs. Thus, the biopsy recommendation for solid NCNs >10 mm changed to a 3-month follow-up LDCT for all solid NCNs <15.0 mm in diameter. If, on follow-up LDCT, the solid NCN had grown at a malignant rate, biopsy was recommended. We found that none of the participants ultimately diagnosed with lung cancer had disease stage progression by waiting 3 months for another LDCT. A further lesson learned was that the fine-needle aspiration biopsy was useful in diagnosing small benign NCNs, thus reducing unnecessary surgery.

For solid larger NCNs (≥15 mm), the standard recommendation called for biopsy or PET scans. But only 50% of solid NCNs ≥15 mm on the baseline LDCT (Fig. 4A), and only 26% on annual repeat screening (Fig. 4B), are malignant. As volumetric accuracy increases in the future, many unnecessary surgical biopsies may be averted, as growth will be more rapidly and accurately assessed, perhaps in weeks rather than months. Such advances will also allow for a more personalized treatment of diagnosed lung cancers.

We are continuing to study growth rates of lung cancers and have confirmed that lung cancer VDTs typically range between 30 and 400 days. We have used this information to determine the minimum follow-up time to assess growth at a malignant rate, ideal time between repeated rounds of screening, and also for extent of treatment decisions.

FURTHER REFINEMENT OF GROWTH ASSESSMENT

The I-ELCAP Investigators recognized the considerable variability of CT scanners for growth assessment when they started in the mid 1990s and have continued to refine growth assessment since that time. The variability is due to many factors: the scanner itself, both inherent and adjustable CT acquisition parameters and characteristics of the person being scanned and the nodule itself, and both morphologic features and location. Unfortunately, the inherent variability of CT scanner acquisition protocols is not widely recognized.

To better illustrate the variability, R. Avila, together with the I-ELCAP Investigators, used a “pocket phantom” (a perfect sphere with a volume of 15.875 ± 0.05 mm³) in an ongoing clinical trial. R. Avila is a computer scientist, formerly the head of CAD development at General Electric Global Research, and is now a member of the Quantitative Imaging Biomarkers Alliance (QIBA) of the Radiologic Society of North America. The pocket phantom, shown in Figure 5, was placed on the chest of the patient while the CT scans were obtained at different times during the trial. These repeated CT acquisitions of the pocket phantom showed up to 44% volume change of the unchanged sphere embedded in the pocket phantom. This level of volumetric change error can lead physicians to a mistaken conclusion that significant volumetric growth (false positive) or volumetric regression (false negative) has occurred.

The current I-ELCAP protocol specifies the necessary change in the nodule diameter to determine “real” growth (see Tables 3 and 4 in the protocol) for tumors with a VDT of 180 days, separately for the baseline and annual repeat rounds. These tables are based on the assumption that 64-detector-row or higher CT scanners are used, that acquisition is at submillimeter slice thickness, slice spacing is equal or less than slice thickness, reconstruction field of view is <30 cm, and that identical acquisition parameters were used to acquire both scans, so that excellent CT images are obtained for accurate growth assessment. The ACR LungRADS recommendations are different, as they specify growth for a nodule, regardless of size, as “an increase of 1.5 mm or more.” The accuracy of VDT calculations, however, depends on nodule size, and thus the use of a fixed value (ie, 1.5 mm) to indicate nodule growth means that smaller tumors with faster doubling time will have delayed recognition. This size dependence is recognized in the I-ELCAP and the QIBA small nodule profile recommendations.

Lessons learned include that when using any computer-assisted software for size or growth assessment, the radiologist must be satisfied with the CT image quality and the computer segmentation results in deciding whether growth has occurred. The computer scans and the segmentation need to be reviewed for image quality (eg, motion artifacts) and for the quality of the segmentation. The radiologist should visually inspect both nodule image sets side-by-side to verify the quality of the computer segmentation for each image that contains a portion of the nodule. The segmentations should also be examined for errors; for example, a small blood vessel may be included as part of a nodule in one segmentation but not in another segmentation. Scan slice thickness and slice spacing for the purpose of volumetric analysis should not exceed 1.25 mm but preferably be as low as possible. We currently use the thinnest slice thickness, typically 0.5 or 0.625 mm.

Spatial warping also complicates measurement accuracy. It occurs when CT images are obtained for LDCT screening, which uses the helical acquisition mode to obtain the images in a single breath-hold. Spatial warping distorts CT images, as illustrated in Figure 6, and the extent of the warping is highly dependent on the make and model of the CT scanner and on the distance from the isocenter.

To address accurate CT measurements, the Radiological Society of North America (RSNA) created the QIBA and has worked with R. Avila to develop a phantom for conformance testing of different scanners and software products. It is far more rigorous for lung nodule measurement assessment than the usual ACR CT accreditation phantom. QIBA is in the final stages of releasing the QIBA CT Small Lung Nodule Profile, which will provide recommendations on assessing growth of small lung nodules.
While these estimates are meant only as boundaries to be confident that nodule change has actually occurred, they do not address the accuracy of volumetric assessment of growth rates themselves, that is, VDTs, which remains a topic of research.

R. Avila developed the QIBA lung nodule profile calculator (https://accumetra.com/QIBA-nod-profile-calculator/), which provides the 95% confidence interval for any diameter or volume measurement of small NCNs and provides a confidence interval for change over time. Currently, it is recommended that estimates of VDTs or changes in nodule size be interpreted with caution. Figure 7 illustrates a follow-up CT scan in 90 days of a 6.0 mm nodule, even when using acquisition parameters that provide the maximum resolution for small NCNs, a stable NCN cannot be distinguished from an NCN with a 400-day VDT, nor between a stable NCN and an NCN with a 180-day VDT. In other words, a 6.0 mm cancer with a VDT of 400 days or a cancer with a VDT of 100 days would...
have follow-up measurements in the overlapping solid orange and red bands, and a stable 6.0 mm diameter NCN with a diameter measurement error of 0.5 mm will have follow-up measurements within the solid green band only 67% of the time.

In the future, phantoms together with the methodology provided by the QIBA CT Small Lung Nodule Pro file will establish the measurement error for different scanners, acquisition protocols, and nodule presentation subtypes. The phantoms, if embedded into or placed on the CT scanner table, will provide automated measurement of an NCN and its confidence interval. This confidence interval can then be used to generate the appropriate time interval within which an individual should return for the follow-up CT imaging to reliably assess change.

**COMPARISON OF I-ELCAP REGIMEN WITH 2 OTHER SCREENING REGIMENS**

The latest I-ELCAP regimen of screening is available on the I-ELCAP website and is also summarized in this report (Table 1 for the baseline round and Tables 2 for all other screening regimens).

**TABLE 1. I-ELCAP Baseline Round of Low-Dose CT (LDCT) Screening**

Before the participant receives the LDCT, ask the participant to cough vigorously. If there is a Solid Endobronchial Nodule, ask them to cough again and repeat LDCT immediately. If only recognized later, ask participant to return for repeat CT in 1 mo and, if still present, see pulmonologist.

The result of baseline LDCT is classified into four IELCAP categories as follows:

**Negative:** Return for first annual screening in 12 mo  
If there are NO noncalcified nodules (NCNs)  
(IELCAP = 1)

**Semi-positive/indeterminate:** Return for first annual screening in 12 mo  
Only nonsolid nodules are present, they can be of any size  
Largest solid NCN < 6.0 mm or largest solid component of a part-solid NCN < 6.0 mm  
(IELCAP = 2)

**Semi-positive/indeterminate:** Return for LDCT follow-up in 3 mo  
Largest NCN is solid and 6.0-14.9 mm in average diameter  
Largest NCN is part-solid and the solid component ≥ 6.0-14.9 mm in average diameter.  
(IELCAP = 3)

**If 3-month LDCT:**

1. **Does NOT show malignant growth:** Return for first annual screening in 9 mo  
   (IELCAP = 4)

2. **Shows malignant growth, the result is positive (see below)**  
   *(If possible infection, recommend pulmonology consultation and possible antibiotics)*

**Positive:** Biopsy or, if less suspicious, PET or 1 mo follow-up LDCT  
Largest solid NCN ≥ 15.0 mm  
(IELCAP = 4)

If there is no diagnosis of malignancy after workup, recommend first annual screening, 12 months after the initial, baseline LDCT.

Use the Society of North America Quantitative Imaging Biomarker Alliance (QIBA) http://accumetra.com/solutions/qiba-lung-nodule-calculator or I-ELCAP recommendations on http://www.IELCAP.org.

Alternatively, calculate VDT = volume doubling time for lung cancers. There is considerable error in VDT measurements: VDT of lung cancers range between 30 days and 400 days. A cancer with VDT of 30 days is a very fast growing cancer; VDT of 400 days is a very slow growing cancer. VDT below 30 days usually indicates infections.
TABLE 2. I-ELCAP Annual Repeat Rounds of Low-dose CT Screening

Before the participant receives the LDCT, ask the participant to cough vigorously. If there is a Solid Endobronchial Nodule, cough again and repeat LDCT immediately. If only recognized later, ask the participant to return for repeat CT in 1 mo and, if still present, see pulmonologist

The result of annual LDCT is:

**Negative:** Return for next annual screening in 12 mo

- If there are no new noncalcified nodules (NCNs).

**Semipositive/indeterminate:** Return for next annual screening in 12 mo

- Only new or growing nonsolid nodules, of any size
- Largest new or growing solid NCN < 3.0 mm
- Largest solid component of a part-solid NCN < 3.0

**Semipositive/indeterminate:** Return for LDCT follow-up in 6 mo

- Largest new or growing solid NCN 3.0-5.9 mm
- Largest solid component of a new or growing part-solid NCN 3.0-5.9 mm

**If 6-month LDCT does NOT show malignant growth:** Return for next annual screening in 6 mo

- Largest NCN is solid 6.0-14.9 mm in average diameter
- Largest NCN is part-solid and the solid component ≥ 6.0-14.9 mm in average diameter

**If 1-mo LDCT:**

1. **Does NOT show malignant growth:** Return for next annual screening in 11 mos
2. Shows malignant growth, the result is positive (see below)

*If possible infection, recommend pulmonology consultation and possible antibiotics

**Positive:** Biopsy or if less suspicious, PET or 1 mo follow-up LDCT

- Largest solid NCN ≥ 15.0 mm

If no diagnosis of malignancy after workup, recommend next annual screening (for IELCAP 3) in 6 months and (for IELCAP 4) in 11 months.

Any participant diagnosed with lung cancer in baseline or annual repeat screening and treated for curative intent should continue annual CT screening or more frequently if recommended by the treating physician. For the first 2 years after surgery, however, the American Society of Clinical Oncologists (ASCO) recommends that, for the first 2 years, LDCT screening should be performed at 6-month intervals.

subsequent annual repeat rounds). The original I-ELCAP protocol required fewer additional diagnostic tests and biopsies for each resulting diagnosis of lung cancer than the new LungRADS and the European Consortium protocol. ACR-LungRADS has 2 scenarios for NCNs ≥ 8 mm but < 15 mm, Scenario 1 recommending immediate PET scans and Scenario 2 recommending follow-up CT in 3 months. Defining the efficiency ratio (ER) as the number of participants requiring further tests per diagnosis of lung cancer, the overall ER was 13.9, 18.3, 18.3, and 31.9 for I-ELCAP, ACR-LungRADS (Scenario 1), ACR-LungRADS (Scenario 2), and the European Consortium, respectively. An ER closer to 1 indicates a more efficient protocol. A more critical ER value is the number of invasive biopsies required per diagnosis of lung cancer, and this was 2.2, 2.1, 1.9, and 3.4, respectively. Thus, I-ELCAP had a lower ER value for the overall workup and for invasive biopsies as well.

Despite the differences, the comparison showed that all 3 regimens have certain key elements in common. All recommend annual screening, and provide thresholds to recommend workup, separately for the baseline and annual repeat rounds of screening. Size threshold values for NCNs are based on either diameter or volume, but threshold values are different. All 3 protocols address the different subtypes of nodule consistency—solid, part-solid, and nonsolid—using terminology developed by I-ELCAP Investigators.

As different regimens of screening are being used, lessons learned include that efficiency metrics need to be developed to provide quantitative methods to compare different protocols. Such metrics also provide insight on the impact of different thresholds and workup recommendations and allow identification for further improvements in the screening regimen that optimize the benefit of early detection. Since the publication of this comparison of these regimens, the ACR has updated LungRADS 1.176 and addressed some of the points that the comparison article had raised.

LESSONS LEARNED ABOUT STAGING

When ELCAP started in 1992, the Sixth Edition of the American Joint Committee on Cancer was being used. It classified lung cancers <30 mm as Stage IA (T1N0M0) into 2 size categories. From the beginning, EL CAP and I-ELCAP used 3 size categories: ≤ 10, 11 to 20, and 21 to 30 mm, and these 3 categories are now incorporated in the Eighth Edition of Lung Cancer Stage Classification introduced in 2018. The Eighth edition had only a limited number of small (<30 mm) lung cancer cases for analysis, with 781 cases being <1.0 cm, limiting the assessment.

The Eighth edition does not recognize nodule consistency (solid, nonsolid, part-solid) as a separate staging criterion, although it has been recognized in the pathologic staging. Non-solid or part-solid cancers are all adenocarcinomas, but the extent of tumor invasion is important. It was recognized that the old terminology “BAC” was unclear whether tumor invasion was required. Therefore, pathologists replaced the old terminology with the following new terminology: adenocarcinoma-in-site, minimally invasive adenocarcinoma. New terminology was also introduced for subtypes of invasive adenocarcinoma depending on the predominant pattern (eg, lepidic, solid, acinar).

It was also recommended that pathologists review the CT imaging features before making their diagnosis.
I-ELCAP Investigators have shown tumor consistency to be an important diagnostic and prognostic factor of lung cancer survival rates and think that tumor consistency should be included in both the clinical and pathologic staging classification, particularly for lung cancers 30 mm or less in maximum diameter. A review of PET and CT scans of lung cancer patients showed that the current FDG-PET criteria for mediastinal lymph node metastases have very low sensitivity, suggesting that mediastinal lymph nodes whose short axis is <20 mm be used as the criterion for clinical Stage IA. The need for updating the eighth edition has been recognized by the International Association for the Study of Lung Cancer, and it has already started.

For multiple adenocarcinomas without lymph node (N0) or distant metastases (M0) <30 mm in maximum diameter, I-ELCAP staging remains different from the eighth classification. I-ELCAP classifies such cases as multiple primaries (T1N0M0), as they have the same survival rates as solitary T1N0M0 adenocarcinomas, if resected. The eighth edition, however, assigns multiple adenocarcinomas to higher stages depending on their respective lobe locations with chemotherapy recommended rather than surgery.

LESSONS LEARNED ABOUT TREATMENT

Breast cancer treatment provides an excellent paradigm of the impact of screening on diagnosis, staging, and treatment of a cancer. Before screening, radical mastectomy with lymph node dissection was the standard-of-care, but, since then, many alternative and less radical treatments have been developed, resulting in better long-term outcomes. Concerns about overdiagnosis and overtreatment of certain subtypes of breast cancer were also raised, resulting in updates in diagnostic workflow. Many of the discussions and controversies in breast cancer screening in the past have or will also arise for lung cancer screening.

The curative treatment of early lung cancer ultimately determines how beneficial the screening actually is, as illustrated in the ELCAP Design (Fig. 1). Similar to breast cancer screening, lung cancer screening has led to significant updates in staging and to more personalized treatment for lung cancer. LDCT screening has already led to significant changes in the pathologic classification and in the staging Classification. Treatment recommendation of lobar resection of Stage I lung cancers, however, has not changed in >50 years. Screening results stimulated 2 randomized surgical trials comparing lobectomy with sublobar resection, which started in 2007, one in the Japan and the other in the United States. Both anticipate publishing their final results around 2020, and their interim reports are encouraging, as both have shown extremely low rates of surgical deaths.

New technologies have been introduced, such as robotic surgery, navigational bronchoscopy, and ablation approaches, and, in the future, there will be further innovations. None of these, however, have had critical assessment, and, often, there are only limited data for small lung cancers. Published cohort studies using the I-ELCAP database have already provided timely outcome results, and Quality of Life measures will become an increasingly important consideration in treatment determination given the high long-term cure rates of screen-diagnosed lung cancer.

In the future there will no doubt be further assessment of new treatments in a timely manner, and the Initiative for Early Lung Cancer Research on Treatment (IELCART) was started using the same prospective cohort design used for I-ELCAP. The ELCAP Management System, used for both management and research purposes allowed for the accumulation of over 82,000 participants with clinical data, imaging, and biologic specimens, has been adapted for the multi-institutional, international IELCART database. The system also allows for randomization for future innovative randomized trials. The vision for IELCART is to become as productive as I-ELCAP has been in producing ongoing screening evidence.

THE IMPORTANCE OF A MANAGEMENT SYSTEM: DEVELOPMENT OF AN OPEN-SOURCE VAPALS-ELCAP MANAGEMENT SYSTEM

Since the earliest days of I-ELCAP, and through each of its conferences and evolution of the management system, there has been an appreciation for the power of collaboration and open science. This same philosophical underpinning inspired the distribution of the I-ELCAP management system to >82 health care institutions in 10 countries. In 2017, I-ELCAP entered into an all-together new collaboration by partnering with the Veterans Health Administration (VHA). Through a generous grant from the Bristol-Myers Squibb Foundation, I-ELCAP contributed its code and forms to develop the Veterans Affairs Partnership to Increase Access to Lung Screening (VA-PALS) and allowed it to be translated into an open-source version for rapid deployment across VHA networks. Named the VAPALS-ELCAP management system, it adopted input from a multidisciplinary group of VA clinicians and software developers who are familiar with the VHA’s electronic health information management system. It was translated into MUMPS programming language and received the highest level of certification from the Open Source Electronic Health Record Alliance (OSEHRA) in May 2019. It is currently being deployed at the 10 VA medical centers that are a part of the VA-PALS initiative, and it offers a structured and reliable reporting and tracking system, which is currently recommended for VA medical centers that offer broad-based screening services.

The VAPALS-ELCAP Management System provides a common terminology for characterization of all NCNs and other LDCT findings, which allows for improved quality assurance of screening, and for pooling of data. As a result, large VA data sets will be developed, which will provide further insights and opportunities for future artificial intelligence (AI) development. The VAPALS-ELCAP system is also freely available for distribution through an Apache v2.0 license, and can be evaluated through an on-line demo: http://demo.va-pals.org/vapals.

The ELCAP Management System will also become available as an open-source system. It is currently being used in hospital settings and provides the required Medicare and Medicaid Services (CMS) information on each radiology report and transmission to a CMS-approved registry as well.

THE FUTURE VISION

In the 20 years since our initial ELCAP report in 1999, a vibrant community of LDCT investigators has emerged. The low-cost and efficient ELCAP design provided the fundamental clinically relevant information about the benefit of LDCT screening, which stimulated large national screening trials. I-ELCAP is providing the relevant data for consideration of expansion of the screening criteria, particularly to women, never smokers exposed to second-hand smoke, and to people of younger age.
Given all the information and publications that have accumulated over the past 20 years (Tables 3), it was realized that LDCT screening provides a comprehensive “health check” of the lungs, heart, and other organs visualized on the LDCT. This vision is gaining increasing recognition throughout the world. An entire session at the 2019 20th WCLC in Barcelona, Spain, in September 2019, was devoted to these other findings.190 I-ELCAP protocol recommendations for these other findings were developed together with relevant medical specialties, with the recognition that these are findings in asymptomatic screening participants and not in patients presenting to physicians with symptoms. Initial focus was on the cardiac findings in 46,47 and emphysema, 48,55,57 which together with lung cancer are the 3 big killers of older smokers. This focus has now been expanded to consider the other findings on the LDCT of the chest, and the recommendations are provided in the I-ELCAP protocol.45

Such a comprehensive “health check” optimal LDCT screening requires a carefully specified, validated regimen that provides for identification and interpretation of critical LDCT findings and the appropriate follow-up recommendations. The regimen should strive to maximize the likelihood of early diagnosis of lung cancer while minimizing unnecessary invasive workup. The importance of having a well-defined regimen was demonstrated by the comparison of I-ELCAP results with those of the NLST, which did not specify a regimen. I-ELCAP’s higher percentage of Stage I diagnoses and long-term survival rates compared with those of the NLST, after consideration of multiple alternative explanations, was due to the I-ELCAP regimen.181 Aside from a well-defined regimen, appropriate radiologic interpretation can minimize unnecessary workup and interventional procedures. It has also been shown that high-quality LDCT screening can be performed in academic or community settings as long as a quality assurance process is in place.182

LDCT radiation doses are currently below the dose of mammographic studies. Ultra LDCT, at radiation doses approaching those of CXR, is now being used for evaluation of chest diseases, including lung cancer and asbestos.183-186 New image analytics and statistical techniques have been developed, with even more innovations on the horizon. Future image interpretation will be increasingly assisted by computer-aided diagnostics,187-197 which already had started in the 1990s.120-125,198-204 Further developments will continue to improve 3-dimensional VDT, which was already introduced in the mid 1990s by ELCAP.119-125

AI techniques in the field of medicine are gaining more interest recently, but it should be recognized that initial efforts had started as early as the 1970s, including by ELCAP Investigators.205-213 Because of enhanced algorithms and computing power, AI is now rapidly expanding and has generated great enthusiasm for streamlining cancer screening to improve early detection and diagnosis of cancer and personalize treatment and outcome prediction.215-221

We are at the beginning of a remarkable transformation in radiologic interpretation that will lead to dramatic improvements in the regimen of screening and facilitate reporting. In making this transformation, it is important to understand the underpinnings of current protocols. Thus, this report focuses on the rationale of the regimen itself, importance of measurement accuracy for timely follow-up and accurate growth assessment of CT-detected NCNs, and the need to limit unnecessary invasive procedures. As already seen in the past 20 years since screening was introduced, understanding of the pathologic findings of small lung cancers has increased, and screening has stimulated advances in the treatment of early lung cancer, which in turn has led to updates in the staging criteria.

ACKNOWLEDGMENTS

The authors express their deepest gratitude to the many physicians, nurses, patient coordinators, academicians, and technical and administrative staff whose dedicated and meticulous work over the past 3 decades has provided the platform on which I-ELCAP research is built. Very, very special thanks to the thousands of screening participants who have allowed the authors to follow their progress over the years so that others could benefit from the information gleaned from their experiences. They greatly appreciate their generosity of spirit. The multidisciplinary team of authors have participated in the development of LDCT screening, its key results, and its latest updates. The team consists of radiologists, pulmonologists, statisticians, and electrical and computer scientists. Key innovators in their respective countries were the following physicians. Dr Shaha, a radiologist, was the first ELCAP screening fellow in 1996, and she participated in the development of the initial protocol updates, set up screening in her

---

**TABLE 3. Summary of I-ELCAP Innovations, Initial Year, and Publications**

| Development of the ELCAP Design | 1992 | 3–6 |
|---------------------------------|------|-----|
| Baseline ELCAP Results          | 1998 | 6–8 |
| Annual Repeat Results           | 1999 | 9,10|
| Survival benefit of LDCT screening | 1999 | 8,18|
| Neural networks in LDCT screening | 1994 | 203,206,207|
| Volume-doubling assessment of NCNs | 1997 | 119–129|
| International Conferences on Screening for Lung Cancer | 1999 | 21–29|
| Cost-effectiveness of Low-Dose CT Screening | 2000 | 50–52|
| Web-based ELCAP Management System: data and images | 2001 | 16|
| Smoking cessation integrated into screening | 2001 | 15,105–116|
| I-ELCAP protocol development | 2001 | 19,24|
| Updates of positive result | 2001 | 67,70,71|
| Expansion to NY-ELCAP and I-ELCAP | 2001 | 17,18|
| Identification and terminology of nonsolid and part-solid NCNs | 2002 | 81–85,96–101|
| Watchful waiting for nonsolid and part-solid NCNs | 2002 | 24,45|
| I-ELCAP pathology, protocol, and panel results | 2002 | 84–91,141,142|
| Increased lung cancer risk of women | 2004 | 173,174|
| Individualization of risk of lung cancer and competing causes of death | 2005 | 39–42|
| Comparison of screening study designs | 2005 | 35–37|
| CT findings of cardiac disease | 2006 | 45–47|
| Emphysema, and other findings | 2007 | 45,47,48,55|
| Treatment of screen-diagnosed cancer patients and quality of life | 2013 | 160–169|
| Initiative for Early Lung Cancer Research on Treatment (IELCART) | 2018 | 58|
| Recommended updates of staging criteria | 2019 | 8,100,153,154|
| Comparison of different screening protocols | 2019 | 145|

---

This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.
country, and has been a key driver in implementation of screening in her country, Israel.53 Dr Zuhleta, a pulmonologist, started the first I-ELCAP screening program in 1999 in Pamplona, Spain and focused on the integration of pulmonary function and emphysema assessment into the screening regimen.48,55,57 This I-ELCAP group published the first report showing that the presence of emphysema on an LDCT in the context of lung cancer screening is independently associated with an increased risk for death from lung cancer and COPD,48 a finding confirmed by several studies thereafter. Dr Aguayo, a pulmonologist at the Phoenix Veterans Affairs Health Care System (VAHCS), was our latest member to join the I-ELCAP team when he introduced the I-ELCAP protocol in 2014 in a clinical trial of smoking cessation with LDCT screening and has provided screening ever since and participated in screening research.146 Subsequently, and leveraging the ongoing collaborative efforts between Phoenix VAHCS and I-ELCAP, Dr Moghaddasi organized the Veterans Administration Partnership to Increase Access to Lung Screening (VA-PALS), obtaining funding from the Bristol-Myers-Squibb Foundation172 and serving as Principal Investigator. The VA-PALS team recognized the importance of having a management system for the entire screening process and the need for continuous quality assurance and their collaboration resulted in the development of an open-source management process and software, called the VAPALS-ELCAP Management System,173 which is freely available to the world. Dr Aguayo and his team at the Phoenix VAHCS are the alpha test team for the resulting VA-PALS-ELCAP Management System, which is launching throughout the VA Health Care System.

REFERENCES

1. Henschke CI, Yankelevitz DF, Reeves AP, et al. Evolution of lung cancer screening management. Oncology (Williston Park). 2019;33:629380.
2. Henschke C, Boffetta P, Yankelevitz D, et al. Computed tomography screening: the international early lung cancer action program experience. Thorac Surg Clin. 2015;25:129–143.
3. Henschke CI, Miettinen OS, Yankelevitz DF, et al. Radiographic screening for cancer proposed paradigm for requisite research. Clin Imaging. 1994;18:16–20.
4. Henschke C, Caro J, Libby D, et al. Radiographic screening for lung cancer: proposed paradigm for requisite research. Clin Imaging. 1994;18:16–20.
5. Henschke C, Smith J, Libby D, et al. New Concepts for Lung Cancer Screening: Paradigm For Outcomes Research. Seattle, WA: American Thoracic Society; 1995:21–24.
6. Henschke C, McCauley D, Yankelevitz D, et al. Early Lung Cancer Action Program (ELCAP): baseline results of low-dose screening CT for lung cancer. Radiological Society of North America (RSNA) 84th Scientific Assembly and Annual Meeting. Radiology. 1998;209(suppl):17–82.
7. Henschke C. CT Screening For Lung Cancer. Barcelona, Spain: European Thoracic Society Scientific Session; 1999.
8. Henschke C, McCauley D, Yankelevitz D, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99–105.
9. Henschke C, McCauley D, Yankelevitz D, et al. Early Lung Cancer Action Program (ELCAP): Annual Report Results of Low-Dose Screening CT For Lung Cancer. Chicago, IL: Radiological Society of North American (RSNA) Scientific Session; 1999.
10. Henschke C, Naidich D, Yankelevitz D, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer. 2001;92:153–159.
11. Grady D. CAT scan process could cut deaths from lung cancer. Small tumors detected. New York Times. 1999.
12. Hutchinson G, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst. 1968;41:665–681.
13. Prorok P, Chamberlain J, Day N, et al. UICC workshop on the evaluation of screening programmes for cancer: Meeting held in Venice, Italy, on November 14–16, 1983. Int J Cancer. 1984;34:1–4.
14. Morrison AS. Screening in Chronic Disease 2nd ed Monographs in Epidemiology and Biostatistics. New York, NY: Oxford University Press; 1992:254.
15. Henschke CI, Salvatore M, Cham M, et al. Baseline and annual repeat rounds of screening: implications for optimal regimens of screening. Eur Radiol. 2018;28:1085–1094.
16. Reeves A, Kostis W, Yankelevitz D, et al. A Web-based database system for multi-institutional research studies on lung cancer. Radiology. 2001;221:372.
17. NY-ELCAP Investigators. CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project. Radiology. 2007;243:239–249.
18. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with lung cancer detected on CT screening. N Engl J Med. 2006;355:1763–1771.
19. Henschke C, Yankelevitz D, Smith J, et al. ELCAP Group. Screening for lung cancer: the early lung cancer action approach. Lung Cancer. 2002;35:143–148.
20. Field JK, Brambilla C, Caporaso N, et al. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol. 2002;21:369–373.
21. Hirsch FR, Bunn PA Jr, Dmistrvsk E, et al. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002;37:325–344.
22. Abraham D, Goitein O, Yankelevitz D, et al. Screening for lung cancer using low-dose radiation-dose computed tomography. Imaging Decis MRI. 2002;6:4–13.
23. Henschke CI, Yankelevitz DF, McCauley DI, et al. Guidelines for the use of spiral computed tomography in screening for lung cancer. Eur Respir J Suppl. 2003;39:45s–51s.
24. International Early Lung Cancer Action Program Investigators. Program and Consensus statements. International Conferences on Screening for Lung Cancer. Available at: http://events.icalcap.org/conferences/past. Accessed April 20, 2020.
25. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest. 1992;101:1013–1018.
26. Flehinger BJ, Kimmel M, Polyak T, et al. Screening for lung cancer. The Mayo Lung Project revisited. Cancer. 1993;72:1573–1580.
27. National Cancer Advisory Board. National Cancer Institute. Spiral Computed Tomography (CT) Scanning for Detection of Lung Cancer. National Cancer Advisory Board 111st Regular Meeting Minutes. September 23–24, 1999. Available at: https://deainfo.nci.nih.gov/advisory/ncab/archive/111_0999/nca0999.pdf. Accessed April 20, 2020.
28. Auerle D, Adams A, Berg C, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
29. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:668–874.
30. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361:2221–2229.
31. de Koning H, Van der Aalst C, Ten Haaf K, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J Thorac Oncol. 2018;13:5185–5185.
32. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503–513.
33. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev.* 2012;21:308–315.

34. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. *Ann Oncol.* 2019;30:1162–1169.

35. Henschke CI, Altorki N, Farooqi A, et al. An update of CT screening for lung cancer. *Semin Ultrasound CT MRI.* 2005;26:348–356.

36. Henschke CI, Boffetta P, Gorlova O, et al. Assessment of lung-cancer mortality reduction from CT screening. *Lung Cancer.* 2011;71:328–332.

37. Foy M, Yip R, Chen X, et al. Modeling the mortality reduction due to computed tomography screening for lung cancer. *Cancer.* 2011;117:2703–2708.

38. International Association for the Study of Lung Cancer (IASLC). IASLC 2019 WCLC World Conference on Lung Cancer Barcelona, Spain, September 7–10, 2019.

39. I-ELCAP Investigators. Screening for lung cancer: individualized benefit by risk indicators for the first round of screening. American Society of Clinical Oncology Scientific Session, 2005.

40. International Early Lung Cancer Action Program Investigators. Computed tomographic screening for lung cancer: individualising the benefit of the screening. *Eur Respir J.* 2007;30:843–847.

41. Henschke C, Yip R, Yankelevitz D, et al. *CT Screening For Lung Cancer: Risk of Dying of Competing Causes of Death.* Orlando, FL: American Society of Clinical Oncology Scientific Session; 2005.

42. Yip R, Henschke CI, Yankelevitz D. CT screening for lung cancer: risk of dying of “competing” causes of death. *J Clin Oncol.* 2005;23:6668–6668.

43. Ostroff J, Buzina D, Mancuso C, et al. Smoking cessation following CT screening for early detection of lung cancer. *Prev Med.* 2001;33:613–621.

44. Anderson CM, Yip R, Henschke CI, et al. Smoking cessation and relapse during a lung cancer screening program. *Cancer Epidemiol Biomarkers Prev.* 2009;18:3476–3483.

45. International Early Lung Cancer Action Program Investigators. *International Early Lung Cancer Action Program protocol.* Available at: www.IELCAP.org/protocols. Accessed January 3, 2018.

46. Shemesh J, Henschke C, Farooqi A, et al. Frequency of coronary artery calcification on low-dose computed tomography screening for lung cancer. *Clin Imaging.* 2006;30:181–185.

47. Shemesh J, Henschke C, Shalam D, et al. Ordinal scoring of coronary calcifications on low-dose CT scans of the chest is predictive of death from cardiovascular disease. *Radiology.* 2010;257:541–548.

48. Zulueta JJ, Wisnivesky JP, Henschke CI, et al. Emphysema scores predict death from COPD and lung cancer. *Chest.* 2012;141:1216–1223.

49. Henschke C. Cost analysis of competing strategies in evaluating and treating solitary pulmonary nodules. Radiological Society of North America (RSNA) 82nd Scientific Assembly and Annual Meeting. *Radiology.* 1996;201(suppl.):1–540.

50. Wisnivesky J, Braz-Parente D, Smith J, et al. Cost effectiveness of low-dose computed tomography screening for non small cell lung cancer. Radiological Society of North America (RSNA) 86th Scientific Assembly and Annual Meeting. *Radiology.* 2000;217(suppl):101-608; 745–931.

51. Pyenson BS, Henschke CI, Yankelevitz DF, et al. Offering lung cancer screening to high-risk medicare beneficiaries saves lives and is cost-effective: an actuarial analysis. *Am Health Drug Benefits.* 2014;7:272–282.

52. Pyenson B, Henschke CI, Yankelevitz DF. Population health’s unanimity on lung cancer screening: far ahead of medical advice. *Am J Transl Med.* 2017:5:2.

53. Shalam D, Breuer R, Copel L, et al. Computed tomography screening for lung cancer: applicability of an international protocol in a single-institution environment. *Clin Lung Cancer.* 2006;7:262–267.

54. Henschke C, Sone S, Markowitz S, et al. *Update on the International Early Lung Cancer Action Program (I-ELCAP).* Chicago, IL: Radiological Society of North America Scientific Session; 2006.

55. Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose ct of the chest. *Chest.* 2007;132:1932–1938.

56. Liu XG, Liang MZ, Wang Y, et al. The outcome differences of CT screening for lung cancer pre and post following an algorithm in Zhuhai, China. *Lung Cancer.* 2011;73:230–236.

57. Sanchez-Salcido P, Wilson DO, De Torres JP, et al. Improving selection criteria for lung cancer screening the potential role of emphysema. *Am J Respir Crit Care Med.* 2015:191:924–931.

58. Flores R, Taioli E, Yankelevitz DF, et al. Initiative for early lung cancer research on treatment: development of study design and pilot implementation. *J Thorac Oncol.* 2018;13:946–957.

59. Olsen L, Aisner D, McGinnis J. *The Learning Healthcare System: Workshop Summary of the Institute of Medicine Roundtable on Evidence-based Medicine.* Washington, DC: National Academy Press (US); 2007–4–10.

60. Naidich DP, Marshall CH, Gribbin C, et al. Low-dose CT of the lungs: preliminary observations. *Radiology.* 1990;175:729–731.

61. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. *Br J Dis Chest.* 1979;73:3–17.

62. Cummings SR, Lilington GA, Richard RJ. Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach. *Am Rev Respir Dis.* 1986;134:449–452.

63. Lilington GA. Management of solitary pulmonary nodules. *Dis Mon.* 1991;37:271–318.

64. Gurney J. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. *Radiology.* 1993:186:405–413.

65. Gurney JW, Lyddon DM, McKay JA. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. *Radiology.* 1993:186:415–422.

66. Gurney JW, Swensen SJ. Solitary pulmonary nodules: determining the likelihood of malignancy with neural network analysis. *Radiology.* 1995;186:823–829.

67. Henschke C, Yankelevitz D, Naidich D, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. *Radiology.* 2004;231:164–168.

68. MacMahon H, Austin JH, Gamsu G, et al. *Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society.* *RadioLOGY.* 2005:237:395–400.

69. MacMahon H, Naidich DP, Goo JM, et al. *Guidelines for the management of incidental pulmonary nodules detected on CT Images: from the Fleischner Society 2017.* *Radiology.* 2017;284:228–243.

70. Henschke C, Yip R, Yankelevitz DF, et al. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. *Ann Intern Med.* 2013;158:246–252.

71. Yip R, Henschke CI, Yankelevitz DF, et al. CT screening for lung cancer: alternative definitions of positive test result based on the national lung screening trial and international early lung cancer action program databases. *Radiology.* 2014;273:591–596.

72. American College of Radiology (ACR). *Lung CT screening reporting & data system (Lung-RADS Version 1.0).* Available at: www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/Lung RADS_AssessmentCategories.pdf?la=en. Accessed September 11, 2019.

73. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. *Ann Intern Med.* 2015;162:485–491.

74. Wood DE, Kazerooni EA, Baum SL, et al. Lung cancer screening, version 3.2018. *J Natl Compr Cancer Net.* 2018;16:412–441.
75. Li KW, Yip R, Avila R, et al. The effect of rounding on rate of positive results on CT screening for lung cancer. *J Thorac Oncol*. 2017;12:5875.

76. American College of Radiology (ACR). Lung-RADS v1.1 Assessment Categories. Available at: www.acr.org/collections/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf?la=en. Accessed September 11, 2019.

77. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. *Radiology*. 1996;201:798–802.

78. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: Histologic characteristics and prognosis. *Cancer*. 1995;75:2844–2852.

79. Kuriyama K, Seto M, Kasugai T, et al. Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung. *AJR Am J Roentgenol*. 1999;173:465–469.

80. Yang ZG, Sone S, Takashima S, et al. Small peripheral carcinomas of the lung: thin-section CT and pathologic correlation. *Eur Radiol*. 1999;9:1819–1823.

81. Mirtcheva RM, Vazquez M, Yankelevitz DF, et al. Bronchioloalveolar carcinoma and adenocarcinoma with bronchioalveolar features presenting as ground-glass opacities on CT. *Clin Imaging*. 2002;26:95–100.

82. Henschke C, Yankelevitz D, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. *AJR Am J Roentgenol*. 2002;178:1053–1057.

83. Sone S, Nakayama T, Honda T, et al. Long-term follow-up study of a population-based 1996–1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. *Lung Cancer*. 2007;58:329–341.

84. Vazquez M, Flieder D, Yankelevitz D, et al. Undetected pathologic lesions in lobectomy specimens of CT detected bronchioloalveolar carcinoma (BAC). *Mod Pathol*. 2001;14:227A.

85. Goitie O, Reeves A, Kostis WJ, et al. Development of a Web-based Radiological-Pathologic Teaching File for Lung Cancer Screening. Chicago, IL: Radiological Society of North America (RSNA) Scientific Session; 2001.

86. Vazquez M, Flieder D, Travis W, et al. Early lung cancer action project pathology protocol. *Lung Cancer*. 2003;39:231–232.

87. International Early Lung Cancer Action Program Pathology Protocol. Available at: http://www.ielcap.org/sites/default/files/pathology_protocol.pdf. Accessed April 20, 2020.

88. Henschke CI. American Cancer Society Grant 2001-2006. NY-ELCAP Pathology Review.

89. Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. *Am J Surg Pathol*. 2006;30:606–613.

90. Carter D, Vazquez M, Flieder DB, et al. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. *Lung Cancer*. 2007;56:193–199.

91. Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. *Lung Cancer*. 2009;64:148–154.

92. Travis W, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/AmERICAN Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*. 2011;6:244–285.

93. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/AmERICAN Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. *Proc Am Thorac Soc*. 2011;8:381–385.

94. Travis W, Brambilla E, Burke A, et al. Introduction to the 2015 World Conference Organization classification of tumors of the lung, pleura, thymus and heart. *J Thorac Oncol*. 2015;10:1240–1242.

95. Travis WD, Asamura H, Bankier AA, et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol*. 2016;11:1204–1223.

96. Yankelevitz DF, Yip R, Smith JP, et al. CT screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds. *Radiology*. 2015;277:555–564.

97. Henschke CI, Yip R, Smith JP, et al. CT screening for lung cancer: part-solid nodules in baseline and annual repeat rounds. *AJR Am J Roentgenol*. 2016;207:1176–1184.

98. Yip R, Yankelevitz DF, Hu M, et al. Lung cancer deaths in the National Lung Sceening Trial attributed to nonsolid nodules. *Radiology*. 2016;281:589–596.

99. Yip R, Henschke CI, Xu DM, et al. Lung cancers manifesting as Part-Solid Nodules in the National Lung Screening Trial. *AJR Am J Roentgenol*. 2017;208:1011–1021.

100. Yip R, Wolf A, Tam K, et al. Outcomes of lung cancers manifesting as nonsolid nodules. *Lung Cancer*. 2016;97:35–42.

101. Yip R, Li K, Liu L, et al. Controversies on lung cancers manifesting as part-solid nodules. *Eur Radiol*. 2018;28:747–759.

102. Libby DM, Smith JP, Altorki NK, et al. Managing the small pulmonary nodule discovered by CT. *Chest*. 2004;125:1522–1529.

103. Libby DM, Wu N, Lee JI, et al. CT screening for lung cancer: the value of short-term CT follow-up. *Chest*. 2006;129:270–276.

104. Esserman L, Thompson I, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. *JAMA*. 2013;310:797–798.

105. Patz EF Jr, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. *JAMA Intern Med*. 2014;174:269–274.

106. National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. *J Thorac Oncol*. 2019;14:1732–1742.

107. Miettinen OS. Screening for lung cancer. *Radiol Clin North Am*. 2000;38:479–486.

108. Miettinen OS, Henschke CI. CT screening for lung cancer: coping with nihilistic recommendations. *Radiology*. 2001;221:592–596.

109. Miettinen OS, Henschke CI. Commentary on Drs Patz, Black, and Goodman’s viewpoint. *Radiology*. 2001;221:598–599.

110. Miettinen OS, Henschke CI. Commentary on “CT screening for lung cancer: not ready for routine practice”. *Radiology*. 2001;221:598–599.

111. Miettinen OS, Henschke CI, Pasmanter MW, et al. Mammographic screening: no reliable supporting evidence? *Lancet*. 2002;359:404–405.

112. Henschke CI, Winsivesky JP, Yankelevitz DF, et al. Small stage I cancers of the lung: genuineness and curability. *Lung Cancer*. 2003;39:327–330.

113. Miettinen OS, Yankelevitz DF, Henschke CI. Evaluation of screening for a cancer: annotated catechism of the Gold Standard creed. *J Eval Clin Pract*. 2003;9:145–150.

114. Altorki NK, Yankelevitz DF, Vazquez MF, et al. Bronchioloalveolar carcinoma in small pulmonary nodules: clinical relevance. *Semin Thorac Cardiovasc Surg*. 2005;17:123–127.

115. Henschke CI, Shaham D, Yankelevitz DF, et al. CT screening for lung cancer: significance of diagnoses in its baseline cycle. *Eur Radiol*. 2006;16:21–15.

116. Miettinen OS, Henschke CI, Smith JP, et al. Is ground glass descriptive of a type of pulmonary nodule? *Radiology*. 2014;270:311–312.

117. Yankelevitz DF, Chan C, Henschke CI. Overdiagnosis: “A Malformed Concept”. *J Thorac Imaging*. 2019;34:151–153.

118. Pagano A, Siddique M, Chung M, et al. Volume doubling time of primary lung cancers in interstitial lung disease. Radiological society of North America. Scientific Assembly and Annual Meeting, Chicago IL, December 1-6, 2019. Available at: archive.rsna.org/2019/19021991.html. Accessed May 27, 2020.
119. Yankelevitz DF. Early Repeat CT for Evaluation of Solitary Lung Nodules. R01-CA-78905. 1999, National Institutes of Health. Available at: https://nctndsearch.cancer.gov/nciportfoliow/search/details?interaction=abstract&grantID=R01CA78905-01A1&grantID=28634774&grntSCDC=FV%202019&absID=637722&absSCDC=CURRENT. Accessed May 27, 2020.

120. Yankelevitz D, Peters E, Zhao B, et al. Can computer aided morphologic analysis of solitary pulmonary nodules predict pathology? Radiological Society of North America (RSNA) 83rd scientific assembly and annual meeting. Radiology. 1997;205(suppl):17–749.

121. Yankelevitz D, Henschke C. Quantitative techniques for evaluating pulmonary nodule morphology. European Congress of Radiology Scientific Session, Vienna, Austria. March 5, 1997.

122. Yankelevitz D, Gupta R, Henschke C. Is early repeat CT feasible for evaluation of pulmonary nodules: first order considerations? Radiological Society of North America (RSNA) 83rd Scientific Assembly and Annual Meeting. Radiology. 1997;205(suppl):17–749.

123. Reeves A, Zhao B, Yankelevitz D, et al. Characterization of three-dimensional shape and size changes of pulmonary nodules over time from helical CT images. Radiological Society of North America (RSNA) 83rd Scientific Assembly and Annual Meeting. Radiology. 1997;205(suppl):17–749.

124. Yankelevitz D, Zhao B, Gupta R, et al. Early repeat CT for assessment of pulmonary nodules. American Roentgen Ray Scientific Session, April 27, 1998.

125. Yankelevitz D, Henschke C. Determination of malignancy in small pulmonary nodules based on volumetrically determined growth rates. Radiological Society of North America (RSNA) 84th Scientific Assembly and Annual Meeting. Radiology. 1998;209:679–17.01.

126. Yankelevitz DF, Gupta R, Zhao B, et al. Small pulmonary nodules: evaluation with repeat CT—preliminary experience. Radiology. 1999;212:561–566.

127. Yankelevitz DF, Reeves AP, Kostis WJ, et al. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology. 2000;217:251–256.

128. Kostis W, Yankelevitz D, Reeves A, et al. Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. Radiology. 2003;225:1259–1274.

129. Kostis W, Yankelevitz D, Reeves A, et al. Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. Radiology. 2006;246:450–450.

130. Arai T, Kuroishi T, Saito Y, et al. Tumor doubling time and impact of different assumptions. Presented at the IASLC 2019–2020. The Regimen of CT Screening for Lung Cancer. J Thorac Imaging. 2019;14:890–902.

131. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990–1003.

132. DeVita V, Lawrence T, Rosenberg S. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins.

133. Nakamura K, Saji H, Nakajima R, et al. A phase III randomized trial of lobectomy versus limited resection for non-small cell lung cancer (JCOG0802/ WJOG4607L). Jpn J Clin Oncol. 2010;40:271–274.
